Moderna, Inc. (ETR:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 9.31B |
| Revenue (ttm) | 2.62B |
| Net Income (ttm) | -2.47B |
| Shares Out | n/a |
| EPS (ttm) | -6.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Average Volume | 929 |
| Open | 23.00 |
| Previous Close | 22.65 |
| Day's Range | 22.87 - 23.00 |
| 52-Week Range | 20.18 - 82.75 |
| Beta | 1.83 |
| RSI | 41.40 |
| Earnings Date | Jul 31, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Bhattacharya and Kennedy split on mRNA cuts
What's Driving the Market Sentiment Around Moderna?
Moderna's (NYSE: MRNA) short percent of float has fallen 4.88% since its last report. The company recently reported that it has 63.02 million shares sold short , which is 22.63% of all regular shares...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
View Preview Pfizer Inc.'s (NYSE: PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and pro...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...
The 3 Things That Matter for Moderna Now
The company is still trying to prove that it isn't just a pandemic play.
RFK Jr has slashed vaccine research. You need to know how perilous that is for the world | Devi Sridhar
The avian flu virus is now just one mutation away from easier transmission among humans. Donald Trump’s health chief is a grave risk to world health Prof Devi Sridhar is chair of global public health ...
Pfizer Covid vaccine for young children may not be renewed by FDA
Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap Pfizer’s Covid vaccine for young children may not be renewed by the US Food and Drug A...
Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company’s vaccines and said it would cancel some contracts and stop fundi...
Check Out What Whales Are Doing With MRNA
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ: MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available opt...
Despite RFK’s funding block, mRNA vaccines are too impressive to ignore
Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research It was a blow many were braced for, yet the block on US funding for mRNA vaccines b...
Is RFK Jr right to pull mRNA vaccine research funding?
The US is withdrawing $500m for vaccines for diseases like flu and Covid. Health correspondent James Gallagher asks if it's the right call.
RFK Jr cancels $500 million in mRNA research, HHS to prioritize 'safer' vaccine alternatives
Trump administration's Health and Human Services Department cancels 22 mRNA vaccine contracts totaling roughly $500 million, with Health Secretary Kennedy announcing a transition to 'safer' alternativ...
Moderna: RSV Upside Slim, Cash Burn Heavy
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
Moderna: Is Now the Time to Buy the Deep Value Dip?
Moderna’s stock has plunged over 95% from its 2021 peak amid falling COVID-19 vaccine sales and mounting financial pressures, but it is now approaching long-term support and shows potential for future...
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio ? 1. Novo Nordisk (NYSE: NVO) has slumped over 31% this week after the company lowered its 2025 sales...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Moderna making effort to stop cash outflows: Analyst
Courtney Breen, Senior Analyst on U.S. Biopharmaceuticals at Bernstein, joins BNN Bloomberg to discuss Moderna's earnings.
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Moderna, Inc. 2025 Q2 - Results - Earnings Call Presentation
Unpacking the Latest Options Trading Trends in Moderna
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ: MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available opt...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2227553133-e6d21cdee8954e4dab5adb3907d89158.jpg)
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Moderna cuts 2025 revenue to $2.2B after UK booster delay
Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 ...